Boston Scientific Corporation $BSX Shares Bought by Guggenheim Capital LLC

Key Points

• Guggenheim Capital LLC has increased its holdings in Boston Scientific Corporation by 8.2%, now owning 127,869 shares valued at approximately $12.9 million.
• Boston Scientific reported a solid quarterly earnings result, with an EPS of $0.75, surpassing estimates, and revenue of $5.06 billion, a year-over-year increase of 22.8%.
• Institutional investors collectively own around 89.07% of Boston Scientific's stock, reflecting growing confidence in the company’s prospects.

Guggenheim Capital LLC increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,869 shares of the medical equipment provider's stock after acquiring an additional 9,678 shares during the period. Guggenheim Capital LLC's holdings in Boston Scientific were worth $12,899,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of BSX. GAMMA Investing LLC grew its holdings in Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after buying an additional 2,556,078 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after buying an additional 1,709,461 shares during the last quarter. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after buying an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after buying an additional 1,664,108 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after buying an additional 1,536,663 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 0.2%

Shares of Boston Scientific stock traded down $0.19 during trading hours on Friday, hitting $105.56. 4,066,860 shares of the company's stock traded hands, compared to its average volume of 5,967,270. The stock has a 50 day simple moving average of $104.53 and a 200-day simple moving average of $102.17. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market cap of $156.41 billion, a PE ratio of 62.83, a PEG ratio of 2.54 and a beta of 0.66. Boston Scientific Corporation has a twelve month low of $79.53 and a twelve month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BSX shares. Truist Financial increased their target price on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Barclays raised their price objective on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Oppenheimer raised their price objective on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Finally, Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $117.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.